CA-ELEGEN
24.1.2024 14:01:35 CET | Business Wire | Press release
Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive both near-term milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
Commercially launched in March of last year, ENFINIA DNA delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. Unlike conventional synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is produced entirely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up under GMP. This technology may save significant time and substantial resources spent iteratively cloning, linearizing and purifying plasmid DNA as well as generating master cell banks. Elegen’s innovation in cell-free DNA manufacturing technology represents a significant leap forward that could power the next generation of mRNA, cell and gene therapies.
This collaboration follows the Early Access Program launched by Elegen in May of last year that offered DNA of longer length and higher complexity to select customers. “Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”
About Elegen
Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124105579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nordic Firms Seek Green, Sovereign AI Infrastructure14.7.2026 11:00:00 CEST | Press release
Renewable power, heat reuse and local data requirements are reshaping private and hybrid cloud choices, ISG Provider Lens® report says Nordic enterprises are adopting private and hybrid cloud infrastructure that combines AI-ready capacity, local residency and low-carbon operations as high-performance workloads and geopolitical risk reshape IT strategies, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm. The 2026 ISG Provider Lens® Private/Hybrid Cloud — Data Center Services report for the Nordics finds that the region is evolving from a hosting destination into a backbone for European data processing. Enterprises are using the Nordics’ renewable energy and natural cooling to support cloud strategies that balance large scale with environmental consciousness and compliance with data sovereignty regulations. “Nordic enterprises are connecting infrastructure decisions to resilien
European Commission Approves Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX for First-Line Treatment of Metastatic Colorectal Cancer with BRAF V600E Mutation14.7.2026 11:00:00 CEST | Press release
ERBITUX in combination with encorafenib and FOLFOX is the first and only approved targeted regimen for the first-line treatment of adult patients with BRAF V600E-mutant mCRCThe approval is based on the pivotal Phase 3 BREAKWATER trial, which demonstrated statistically significant and clinically meaningful improvements in both progression-free survival (PFS) and overall survival (OS) compared to standard chemotherapy with or without bevacizumabERBITUX confirms its status as the pioneering anti-EGFR therapy in mCRC, now approved across different patient populations and multiple lines of therapyNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) — both in first-line treatment in combination
Swiss Pension Funds Increase Commitments to Record Infrastructure Equity Fund to EUR 1.23 Billion14.7.2026 09:58:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), today announced that its Infrastructure Equity fund has attracted EUR 160 million of additional capital from Swiss pension funds, increasing total commitments to approximately EUR 1.23 billion. Capital deployment continues to progress in line with expectations, with more than one-third of the fund’s initial capital now deployed or committed to investments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713541233/en/ RAM manages a dedicated infrastructure co-investment vehicle in partnership with APG, the pension asset manager of ABP, providing Swiss pension funds with access to large-scale infrastructure equity investments alongside APG’s pension fund partners. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of in
Samsung Becomes a Sisvel Wi-Fi Multimode Pool Licensee and Licensor14.7.2026 09:09:00 CEST | Press release
Samsung Electronics has signed up as a licensee of the Sisvel Wi-Fi Multimode pool and has also become a licensor under the programme. The decision by the South Korean company - a global R&D powerhouse and among the world’s top smartphone vendors, as well as a leader in many other electronic product categories - not only confirms the Sisvel Wi-Fi Multimode pool as a recognised solution provider for parties seeking to derisk Wi-Fi implementation but also considerably expands the scope of the programme’s patent offering. Since it was publicly launched in January 2026, ASUS, Hewlett Packard Enterprise, Microsoft and Sony Group Corporation have become licensees of the Sisvel Wi-Fi Multimode pool. There are also five licensor/licensee companies: Huawei, Panasonic, Philips, Samsung Electronics and ZTE. The other licensors are KPN, Mitsubishi Electric, Orange, Aegis 11 SA, SK Telecom and Wilus. The agreement announced today ends litigation in the Eastern District of Texas between Samsung Elec
Wolters Kluwer Integrates Legal Intelligence Platform With Libra Legal AI Workspace in the Netherlands14.7.2026 09:00:00 CEST | Press release
Dutch legal professionals gain access to additional content sources in the Libra by Wolters Kluwer AI workspace, powering a new generation of AI-driven legal work Wolters Kluwer Legal & Regulatory today announced the integration of its Legal Intelligence multi-content-provider platform with the Libra by Wolters Kluwer AI workspace in the Netherlands. Dutch legal professionals will now be able to access more than 5000 additional pieces of expert legal content from Wolters Kluwer and third-party content providers as well as public sources in addition to the existing content offerings in Libra. “By bringing Legal Intelligence into Libra, we move beyond traditional search to truly integrated, AI-driven workflows,” said Rimco Spanjer, Vice President & Managing Director, Wolters Kluwer Legal & Regulatory Benelux. “Combining our authoritative content with trusted third-party sources in one AI workspace enables legal professionals to work smarter every day.” The integration will include truste
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom